STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: The Swedish biotech company Karo Bio (STO:KARO) (Reuters: KARO.ST) today announced that its novel CNS program around ER-beta agonists has been chosen as one of the top 10 most interesting Neuroscience projects available for partnering. The selection was made by the healthcare business analyst Windhover Information Inc, and the independent expert Harry Tracy, Ph.D. and President of NeuroInvestment Research.
